ELV ELEVANCE HEALTH INC FORMERLY revenue, earnings and financials

For the quarter ended September 30, 2026, ELEVANCE HEALTH INC FORMERLY reported revenue of $51.4B (up 1.4% from a year earlier), net income of $1.37B and diluted EPS of $6.27; over the last four quarters revenue was $202B and net income $5.14B; for the fiscal year ended December 2025 revenue was $199B, up 12.5% on the year before.

ELV annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $199B, gross profit n/a, operating income $7.20B, net income $5.66B (margin 2.8%), EPS $25.21
• Fiscal year ended Dec 2024: revenue $177B, gross profit n/a, operating income $7.86B, net income $5.98B (margin 3.4%), EPS $25.68
• Fiscal year ended Dec 2023: revenue $171B, gross profit n/a, operating income $8.50B, net income $5.99B (margin 3.5%), EPS $25.22
• Fiscal year ended Dec 2022: revenue $157B, gross profit n/a, operating income $8.28B, net income $5.89B (margin 3.8%), EPS $24.28
• Fiscal year ended Dec 2021: revenue $139B, gross profit n/a, operating income $7.56B, net income $6.16B (margin 4.4%), EPS $24.95

ELV quarterly revenue and earnings

• Quarter ended Sep 30, 2026: revenue $51.4B (up 1.4% year over year), net income $1.37B, EPS $6.27
• Quarter ended Jun 30, 2026: revenue $50.5B (up 1.4% year over year), net income $1.46B, EPS $6.71
• Quarter ended Mar 31, 2026: revenue $50.2B (up 2.6% year over year), net income $1.76B, EPS $8.00
• Quarter ended Dec 31, 2025 (from the annual report): revenue $49.7B (up 9.5% year over year), net income $547M, EPS $2.56
• Quarter ended Sep 30, 2025: revenue $50.7B (up 12.4% year over year), net income $1.19B, EPS $5.32
• Quarter ended Jun 30, 2025: revenue $49.8B (up 13.4% year over year), net income $1.74B, EPS $7.72
• Quarter ended Mar 31, 2025: revenue $48.9B (up 14.8% year over year), net income $2.18B, EPS $9.61
• Quarter ended Dec 31, 2024 (from the annual report): revenue $45.4B (up 6.6% year over year), net income $418M, EPS $1.88
• Quarter ended Sep 30, 2024: revenue $45.1B (up 5.3% year over year), net income $1.02B, EPS $4.36
• Quarter ended Jun 30, 2024: revenue $43.9B (up 0.5% year over year), net income $2.30B, EPS $9.85
• Quarter ended Mar 31, 2024: revenue $42.6B (up 1.0% year over year), net income $2.25B, EPS $9.59
• Quarter ended Dec 31, 2023 (from the annual report): revenue $42.6B (up 6.8% year over year), net income $856M, EPS $3.68
• Quarter ended Sep 30, 2023: revenue $42.8B (up 7.3% year over year), net income $1.29B, EPS $5.45
• Quarter ended Jun 30, 2023: revenue $43.7B (up 13.0% year over year), net income $1.85B, EPS $7.79
• Quarter ended Mar 31, 2023: revenue $42.2B (up 10.7% year over year), net income $1.99B, EPS $8.30
• Quarter ended Dec 31, 2022 (from the annual report): revenue $39.9B (up 9.2% year over year), net income $865M, EPS $3.61
• Quarter ended Sep 30, 2022: revenue $39.9B (up 11.5% year over year), net income $1.60B, EPS $6.62
• Quarter ended Jun 30, 2022: revenue $38.6B (up 14.1% year over year), net income $1.64B, EPS $6.73
• Quarter ended Mar 31, 2022: revenue $38.1B (up 17.6% year over year), net income $1.79B, EPS $7.32
• Quarter ended Dec 31, 2021 (from the annual report): revenue $36.6B, net income $1.19B, EPS $4.86

ELV cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $4.29B, share buybacks $2.61B
• Fiscal year ended Dec 2024: operating cash flow $5.81B, share buybacks $2.90B
• Fiscal year ended Dec 2023: operating cash flow $8.06B, share buybacks $2.68B, dividends $5.92 per share
• Fiscal year ended Dec 2022: operating cash flow $8.40B, share buybacks $2.32B, dividends $5.12 per share
• Fiscal year ended Dec 2021: operating cash flow $8.36B, share buybacks $1.90B, dividends $4.52 per share

ELV balance sheet

• Sep 30, 2026: cash $10.3B, total assets $128B, total liabilities $83.0B, shareholders' equity $44.7B, long-term debt $30.4B
• Jun 30, 2026: cash $10.2B, total assets $126B, total liabilities $81.4B, shareholders' equity $44.9B, long-term debt $30.7B
• Mar 31, 2026: cash $9.66B, total assets $126B, total liabilities $81.8B, shareholders' equity $43.9B, long-term debt $30.8B
• Dec 31, 2025: cash $9.49B, total assets $121B, total liabilities $77.5B, shareholders' equity $43.9B, long-term debt $30.8B
• Sep 30, 2025: cash $8.71B, total assets $123B, total liabilities $78.7B, shareholders' equity $44.0B, long-term debt $31.2B
• Jun 30, 2025: cash $8.56B, total assets $122B, total liabilities $78.1B, shareholders' equity $43.7B, long-term debt $28.2B
• Mar 31, 2025: cash $7.50B, total assets $120B, total liabilities $77.1B, shareholders' equity $42.5B, long-term debt $28.1B
• Dec 31, 2024: cash $8.29B, total assets $117B, total liabilities $75.5B, shareholders' equity $41.3B, long-term debt $29.2B

What is ELV's revenue?

ELEVANCE HEALTH INC FORMERLY reported $202B of revenue over its last four quarters, through September 30, 2026.

Is ELV profitable?

Yes. ELEVANCE HEALTH INC FORMERLY earned $5.14B over the last four quarters.

What is ELV's EPS?

Diluted earnings per share over the last four quarters were $23.54; $6.27 in the latest quarter.

Does ELV pay a dividend?

ELEVANCE HEALTH INC FORMERLY paid $5.92 per share in dividends in the fiscal year ended December 2023.

ELV ownership and insider trades · All stocks